Browsing Tag
Jazz Pharmaceuticals plc
2 posts
Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.32bn in rare epilepsy expansion
Jazz Pharmaceuticals is committing $820 million upfront for Actio Biosciences and ABS-1230, placing a sizeable bet on a genetically targeted epilepsy therapy whose ongoing Phase 1b/2a study could potentially support a U.S. approval filing.
Jazz Pharmaceuticals (JAZZ) builds $4bn oncology option through AbCellera partnership
Jazz could pay AbCellera more than $4 billion across five oncology programmes. Read how the option deal reshapes JAZZ and ABCL growth strategies.